Sagimet biosciences inc.SGMT.US Overview

US StockHealthcare

(No presentation for SGMT)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

SGMT Overall Performance

SGMT AI Analysis & Strategy

SGMT Recent Performance

-0.92%

Sagimet biosciences inc.

1.30%

Avg of Sector

0.61%

S&P500

SGMT PowerScanner

SGMT Key Information

SGMT Valuation Metrics

SGMT Earnings Table

SGMT Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.